Smith & Nephew Plc
13 March 2002
13 March 2002
ANTITRUST WAITING PERIOD ENDS FOR ORATEC TENDER OFFER
Smith & Nephew plc, the global advanced medical devices group, today announced
that the Hart-Scott-Rodino waiting period applicable to Smith & Nephew's tender
offer for all outstanding shares of common stock of ORATEC Interventions, Inc.
(NASDAQ: OTEC) has expired. The tender offer is being made pursuant to an
agreement and plan of merger dated 13 February 2002. The tender offer will
expire at 12:00 Midnight, New York City time, on Thursday, 21 March 2002,
unless the offer is extended.
U.S. Bancorp Piper Jaffray is the dealer manager for the tender offer, American
Stock Transfer & Trust Company is the depositary and Morrow & Co., Inc. is the
information agent.
Enquiries:
Morrow & Co., Inc. Information Agents
Banks & Brokers: In US - (800) 654-2468
Outside US - (212) 754-8000
Stockholders: In US - (800) 607-0088
Outside US - (212) 754-8000
e-mail: ORATEC.info@morrowco.com
About Smith & Nephew
Smith & Nephew plc, (London Stock Exchange: SN), (NYSE: SNN), is a global
advanced medical devices company with a highly successful track record in
developing, manufacturing and marketing a wide variety of innovative and
technologically advanced tissue repair products. These products are primarily
in the areas of bone, joints, skin and other soft tissue. Smith & Nephew have
extensive marketing and distribution capabilities, with established sales in
more than 90 countries. For further information, visit Smith & Nephew's Web
site at www.smith-nephew.com.
Smith & Nephew Endoscopy (www.endoscopy1.com) is one of its major businesses,
and is a world leader in the development and commercialisation of endoscopic
techniques. Within endoscopy, Smith & Nephew is the recognised world leader in
arthroscopy (endoscopic procedures performed on articulating joints).
This information is provided by RNS
The company news service from the London Stock Exchange
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.